Autologous anti-gp100 T-cell receptor gene-engineered peripheral blood lymphocytes (NCI)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAutologous anti-gp100 T-cell receptor gene-engineered peripheral blood lymphocytes (NCI)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Source of cells > Peripheral blood-derivedCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy

Mechanisms of ActionUpdating

TargetsNot applicable

Therapy Area/IndicationsSkin NeoplasmsMelanoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesNational Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNational Cancer Institute

Active IndicationsN/A

Inactive IndicationsSkin NeoplasmsMelanoma

Other Information

ATC CodeN/A